Wednesday, 26 August 2026European Markets

METABOLIC EXPLORER Stock Impressive Jump On Monday, Outperforms Market

Loading stream...

(vianews) - the market ended the session with metabolic explorer (metex.pa) rising 10.58% to €1.11 on monday, after two sequential sessions in a row of losses. cac 40 jumped 0.52% to €7,250.35, following the last session's downward trend on what was a somewhat bullish trend trading session today.

metabolic explorer's last close was €1.00, 76.91% below its 52-week high of €4.34.

about metabolic explorer

metabolic explorer s.a., a biological chemistry company, engages in the development and industrialization of industrial fermentation processes as alternatives to petrochemical processes worldwide. the company also offers propanediol, butyric acid, butyric acid, glycolic acid, amino acid, and l-valine. its products are used in the formulation of cosmetics, textiles, polymer, animal nutrition, and health products or as intermediates for the synthesis of biomaterials. the company was incorporated in 1999 and is based in saint-beauzire, france.

earnings per share

as for profitability, metabolic explorer has a trailing twelve months eps of €-1.17.

revenue growth

year-on-year quarterly revenue growth declined by 26.9%, now sitting on 228.15m for the twelve trailing months.

yearly top and bottom value

metabolic explorer's stock is valued at €1.11 at 22:36 est, way below its 52-week high of €4.34 and way higher than its 52-week low of €0.88.

more news about metabolic explorer (metex.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com